Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioAtla, Inc. BCAB
$3.64
+$0.49 (13.40%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
155773971.00000000
-
week52high
12.15
-
week52low
2.08
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.21195200
-
EPS
-2.74000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 10:59
Описание компании
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 10 авг 2022 г. |
| Credit Suisse | Neutral | Neutral | 10 авг 2022 г. |
| Credit Suisse | Neutral | Outperform | 05 мая 2022 г. |
| HC Wainwright & Co. | Buy | 21 мар 2022 г. | |
| Roth Capital | Buy | 28 июн 2021 г. | |
| JMP Securities | Market Outperform | 15 сент 2022 г. | |
| Credit Suisse | Neutral | Neutral | 04 ноя 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SHORT JAY M PHD | D | 1374475 | 3517 | 31 янв 2023 г. |
| Smith Scott Andrew | D | 318699 | 2181 | 31 янв 2023 г. |
| WALDRON RICHARD A | D | 130630 | 1144 | 31 янв 2023 г. |
| Vasquez Christian | D | 82938 | 229 | 31 янв 2023 г. |
| Sievers Eric | D | 93300 | 654 | 31 янв 2023 г. |
| SHORT JAY M PHD | D | 1377992 | 4667 | 31 дек 2022 г. |
| WALDRON RICHARD A | D | 131774 | 970 | 31 дек 2022 г. |
| Smith Scott Andrew | D | 320880 | 1791 | 31 дек 2022 г. |
| Vasquez Christian | D | 83167 | 194 | 31 дек 2022 г. |
| Sievers Eric | D | 93954 | 554 | 31 дек 2022 г. |
Новостная лента
7 Cheap But Risky Biotech Stocks
Barrons
18 янв 2023 г. в 13:58
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?
Zacks Investment Research
15 ноя 2022 г. в 11:18
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript
Seeking Alpha
06 ноя 2022 г. в 11:47
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Bruce Mackle - Investor Relations Jay Short - Chairman, Chief Executive Officer and Co-Founder Scott Smith - President Philippe Martin - Chief, Clinical Development and Operations Sheri Lydick - Senior Vice President, Commercial Strategy Richard Waldron - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Kelly Shi - Jefferies Tony Butler - ROTH Capital Arthur He - H.C. Wainwright Reni Benjamin - JMP Securities Operator Good day and welcome to the BioAtla Third Quarter 2022 Earnings Conference Call – pardon me, BioAtla.
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
04 ноя 2022 г. в 12:48
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
GlobeNewsWire
27 окт 2022 г. в 08:00
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights.